Minimal residual disease

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (unknown source) 1 substance
Phase I/II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I/II

1 trial
  • Amgen Inc. Commercial
    BLINATUMOMAB
    2025-521671-31-00 3 countries n=6 Orphan
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 1 Phase I/II 0
← All indication landscapes